A nanodrug combining CD47 and sonodynamic therapy efficiently inhibits osteosarcoma deterioration
出版年份 2023 全文链接
标题
A nanodrug combining CD47 and sonodynamic therapy efficiently inhibits osteosarcoma deterioration
作者
关键词
-
出版物
JOURNAL OF CONTROLLED RELEASE
Volume 355, Issue -, Pages 68-84
出版商
Elsevier BV
发表日期
2023-02-02
DOI
10.1016/j.jconrel.2023.01.038
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
- (2022) Nisha Kumari et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Immunogenic cell stress and death
- (2022) Guido Kroemer et al. NATURE IMMUNOLOGY
- Nanocarriers surface engineered with cell membranes for cancer targeted chemotherapy
- (2022) Wen Lei et al. JOURNAL OF NANOBIOTECHNOLOGY
- Targeting nanoparticles to malignant tumors
- (2022) Nikita Sharma et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Emerging photodynamic nanotherapeutics for inducing immunogenic cell death and potentiating cancer immunotherapy
- (2022) Shenwu Zhang et al. BIOMATERIALS
- PCL-PEG copolymer based injectable thermosensitive hydrogels
- (2022) Mithun Rajendra Dethe et al. JOURNAL OF CONTROLLED RELEASE
- Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
- (2022) Nian Jiang et al. Nature Communications
- Immune Cell Membrane‐Coated Biomimetic Nanoparticles for Targeted Cancer Therapy
- (2021) Fatemeh Oroojalian et al. Small
- Recent Advances in Cell Membrane‐Derived Biomimetic Nanotechnology for Cancer Immunotherapy
- (2021) Faisal Raza et al. Advanced Healthcare Materials
- Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development
- (2021) Bryan Oronsky et al. JOURNAL OF MEDICINAL CHEMISTRY
- CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes
- (2021) Akemi Kosaka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
- (2021) Nehal J Lakhani et al. LANCET ONCOLOGY
- Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
- (2021) Christiane Querfeld et al. Lancet Haematology
- Membrane-core nanoparticles for cancer nanomedicine
- (2020) Jianfeng Guo et al. ADVANCED DRUG DELIVERY REVIEWS
- Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix
- (2020) Scott Caroen et al. Expert Opinion on Drug Delivery
- The CD47-SIRPα Immune Checkpoint
- (2020) Meike E.W. Logtenberg et al. IMMUNITY
- Recent Advances in Nanomaterial‐Assisted Combinational Sonodynamic Cancer Therapy
- (2020) Shuang Liang et al. ADVANCED MATERIALS
- A review of emerging bone tissue engineering via PEG conjugated biodegradable amphiphilic copolymers
- (2019) Jiang-Ze Wang et al. Materials Science & Engineering C-Materials for Biological Applications
- First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
- (2019) Branimir I. Sikic et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
- (2019) Sigbjørn Smeland et al. EUROPEAN JOURNAL OF CANCER
- Macrophages and Metabolism in the Tumor Microenvironment
- (2019) Ilio Vitale et al. Cell Metabolism
- Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell ‘don't eat me’ signals off and ‘eat me’ signals on
- (2019) Suchismita Mohanty et al. Molecular Oncology
- Cell Membrane Coating Technology: A Promising Strategy for Biomedical Applications
- (2019) Yao Liu et al. Nano-Micro Letters
- Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis
- (2018) Yu Han et al. CANCER LETTERS
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Cancer Cell Membrane–Biomimetic Nanoparticles for Homologous-Targeting Dual-Modal Imaging and Photothermal Therapy
- (2016) Ze Chen et al. ACS Nano
- RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials
- (2016) Bryan Oronsky et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma
- (2012) Nicholas M. Bernthal et al. CANCER
- Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents
- (2011) E. P. Buddingh et al. CLINICAL CANCER RESEARCH
- Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
- (2009) S. Bielack et al. ANNALS OF ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started